Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Non-Squamous NSCLC Patients Previously Treated With Platinum-Based Chemotherapy in Combination With a Checkpoint Inhibitor
Condition: Non-Squamous Non-Small Cell Lung Cancer Interventions: Biological: Nivolumab; Drug: Sitravatinib; Drug: Docetaxel Sponsors: Mirati Therapeutics Inc.; Bristol-Myers Squibb Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Chemotherapy | Docetaxel | Non-Small Cell Lung Cancer | Research | Study | Taxotere